These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26050962)

  • 1. The Hippo signal transduction pathway in soft tissue sarcomas.
    Mohamed AD; Tremblay AM; Murray GI; Wackerhage H
    Biochim Biophys Acta; 2015 Aug; 1856(1):121-9. PubMed ID: 26050962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAZ and YAP are frequently activated oncoproteins in sarcomas.
    Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
    Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex.
    Merritt N; Garcia K; Rajendran D; Lin ZY; Zhang X; Mitchell KA; Borcherding N; Fullenkamp C; Chimenti MS; Gingras AC; Harvey KF; Tanas MR
    Elife; 2021 Apr; 10():. PubMed ID: 33913810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
    Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
    J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone.
    Isfort I; Elges S; Cyra M; Berthold R; Renner M; Mechtersheimer G; Åman P; Larsson O; Ratner N; Hafner S; Simmet T; Schliemann C; Rossig C; Dirksen U; Grünewald I; Wardelmann E; Huss S; Hartmann W; Trautmann M
    Sci Rep; 2019 Dec; 9(1):19704. PubMed ID: 31873172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis.
    Eisinger-Mathason TS; Mucaj V; Biju KM; Nakazawa MS; Gohil M; Cash TP; Yoon SS; Skuli N; Park KM; Gerecht S; Simon MC
    Proc Natl Acad Sci U S A; 2015 Jun; 112(26):E3402-11. PubMed ID: 26080399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma.
    Slemmons KK; Yeung C; Baumgart JT; Juarez JOM; McCalla A; Helman LJ
    Cancer Res; 2020 Jul; 80(14):3046-3056. PubMed ID: 32354737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas.
    Deel MD; Li JJ; Crose LE; Linardic CM
    Front Oncol; 2015; 5():190. PubMed ID: 26389076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOB1 Mediated Phospho-recognition in the Core Mammalian Hippo Pathway.
    Couzens AL; Xiong S; Knight JDR; Mao DY; Guettler S; Picaud S; Kurinov I; Filippakopoulos P; Sicheri F; Gingras AC
    Mol Cell Proteomics; 2017 Jun; 16(6):1098-1110. PubMed ID: 28373298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of Hippo signaling pathway in regulating osteoclast formation.
    Yang W; Han W; Qin A; Wang Z; Xu J; Qian Y
    J Cell Physiol; 2018 Jun; 233(6):4606-4617. PubMed ID: 29219182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.
    Ye S; Lawlor MA; Rivera-Reyes A; Egolf S; Chor S; Pak K; Ciotti GE; Lee AC; Marino GE; Shah J; Niedzwicki D; Weber K; Park PMC; Alam MZ; Grazioli A; Haldar M; Xu M; Perry JA; Qi J; Eisinger-Mathason TSK
    Cancer Res; 2018 May; 78(10):2705-2720. PubMed ID: 29490948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Hippo signal transduction network for exercise physiologists.
    Gabriel BM; Hamilton DL; Tremblay AM; Wackerhage H
    J Appl Physiol (1985); 2016 May; 120(10):1105-17. PubMed ID: 26940657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPCR-Hippo Signaling in Cancer.
    Luo J; Yu FX
    Cells; 2019 May; 8(5):. PubMed ID: 31072060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine.
    Barry ER; Simov V; Valtingojer I; Venier O
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma.
    Rivera-Reyes A; Ye S; E Marino G; Egolf S; E Ciotti G; Chor S; Liu Y; Posimo JM; Park PMC; Pak K; Babichev Y; Sostre-Colón J; Tameire F; Leli NM; Koumenis C; C Brady D; Mancuso A; Weber K; Gladdy R; Qi J; Eisinger-Mathason TSK
    Cell Death Dis; 2018 Oct; 9(11):1108. PubMed ID: 30382078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelioid Hemangioendothelioma as a Model of YAP/TAZ-Driven Cancer: Insights from a Rare Fusion Sarcoma.
    Lamar JM; Motilal Nehru V; Weinberg G
    Cancers (Basel); 2018 Jul; 10(7):. PubMed ID: 29996478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
    Miesfeld JB; Link BA
    Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common and Distinctive Functions of the Hippo Effectors Taz and Yap in Skeletal Muscle Stem Cell Function.
    Sun C; De Mello V; Mohamed A; Ortuste Quiroga HP; Garcia-Munoz A; Al Bloshi A; Tremblay AM; von Kriegsheim A; Collie-Duguid E; Vargesson N; Matallanas D; Wackerhage H; Zammit PS
    Stem Cells; 2017 Aug; 35(8):1958-1972. PubMed ID: 28589555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.